On this page
The evidence at a glance
The study, in context
The 2021 report describes a small, uncontrolled follow-up of people who received knee injections. It cannot establish a treatment effect against placebo, structural repair or the performance of today’s retail products.
Lee and Padgett: intra-articular BPC 157 for knee pain (2021)
- Study design
- Retrospective single-clinic chart review with telephone follow-up.
- Who or what was studied
- 17 patients identified; 16 reached. Twelve received BPC alone and four BPC plus TB4.
- What was measured
- Recalled pain relief; follow-up timing varied.
- What it found
- Reported relief in 11 of 12 BPC-only recipients and 3 of 4 combination recipients.
- Important limit
- No control group; no standardized functional measures. Symptom reporting does not demonstrate cartilage or tendon repair.
What the percentage leaves out
A response figure needs its denominator and design beside it. This report followed a small clinical series; it did not randomly assign people to BPC or a control. That makes it useful as an early observation while leaving substantial uncertainty about causation. The two-person safety pilot is another distinct record, not a reason to combine unrelated outcomes into one success rate.
A provider detail worth checking
PeptidesRx describes its BPC product as an injectable package. Its advertised purchasing terms do not establish that the knee-report intervention or outcomes apply to that product.
The combination group is a different exposure
Some participants received BPC with TB4. Their reports should not be attributed solely to BPC, and the combined result should not be presented as a controlled comparison between the two approaches. The exact formulation of a contemporary prescription introduces another separate matching question.
Pain relief is not an imaging result
The publication discusses possible repair, but the reported follow-up does not establish regenerated cartilage or fewer surgeries. Those would require their own measurements. Readers should be able to recognize the difference between an observed symptom report, the authors’ interpretation and a proposed future research question.
Put catalog claims under the same scrutiny
The PeptidesRx review records what its BPC package includes and what remains unclear about pharmacy assignment. Our Cienega Medical review separates bottle price from medical-review fees. These service records cannot resolve the clinical limits of the knee paper. A provider should explain the relevance of a citation without replacing its outcome with a more ambitious one.
Questions worth taking to a consultation
Ask how the clinician establishes the cause of pain, what conventional options are relevant, and what evidence supports the proposed intervention. The consultation checklist helps organize that conversation. A website comparison is not an examination, and this small series should not be used to self-select an injection or postpone assessment.
Common questions
Was this a randomized trial?
No. It was a retrospective review with telephone follow-up and no control group.
Did the paper prove cartilage regrowth?
No. Its reported symptom follow-up does not establish structural repair.
Sources & further reading
Primary research, provider documents and policy sources used in this article. Sources do not endorse this publication.
Source review: 2026-10-29. Provider terms and policy documents can change.